New research delivered fresh mechanistic and clinical insights into neurotoxic events associated with CAR‑T cell therapies, identifying pathways and biomarkers linked to neurological adverse events. The work synthesizes imaging, immune profiling and clinical correlations to propose refined monitoring and management strategies for centers delivering CAR‑T treatments. Developers and transplant centers will use these findings to update risk‑mitigation protocols and inform next‑generation CAR designs with improved safety. Clarification: CAR‑T neurotoxicity refers to neurologic complications, including encephalopathy and seizures, seen after CAR‑T infusion.